Welcome!

News Feed Item

Drug Discovery Technologies - A Global Market Overview

NEW YORK, Sept. 1, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:  Drug Discovery Technologies - A Global Market Overview

http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html

The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening.

Worldwide market for drug discovery technologies explored in this study includes Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Others comprising Epigenetics, Metabolomics, Combinatorial Chemistry, Synthetic Biology, Systems Biology and Nanotechnology.

The global market value for the above mentioned technologies is analyzed in USD. High Throughput Screening accounts for a lion's share in global drug discovery technologies market with an expected share of about 30% in 2015 valued at $18 billion followed by Bioanalytical Assays or instruments by about $14 billion.

This 248 pages global market report includes 28 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. This report profiles 56 key global players and 67 major players across the United States – 41; Europe – 16; Asia-Pacific – 7; and Rest of World - 3. The research also provides the listing of the companies that are engaged in technology, contract research services and providers of discovery technologies. The global list of companies covers addresses, contact numbers and the website addresses of 186 companies.

TABLE OF CONTENTS:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 Product Outline

1.1.1 Backdrop

1.1.2 What Is Drug Discovery?

1.1.2.1 Screening and Design

1.1.3 Omics in Drug Discovery and Development

1.1.4 Process of Discovering Improved Drugs Provided by a Technological Revolution

1.1.5 Drug Discovery Technologies

1.1.5.1 Bioanalytical Assays

1.1.5.1.1 Bio-Analytical Techniques

1.1.5.1.2 Sample Extraction

1.1.5.2 Bioinformatics

1.1.5.2.1 Computer-Aided Drug Design

1.1.5.3 Cell Based Assays

1.1.5.3.1 Cell-Based Assays in High-Throughput Screening for Drug Discovery

1.1.5.4 Genomic Technologies

1.1.5.4.1 Drug Discovery

1.1.5.4.2 Clinical Medicine

1.1.5.4.3 New Antibiotics

1.1.5.5 High Throughput Screening

1.1.5.5.1 High Throughput Screening in Drug Discovery

1.1.5.6 Proteomic Technologies

1.1.5.6.1 A Proteomics Approach to Biomarker Discovery and Drug Development

1.1.5.7 Other Technologies

1.1.5.7.1 Epigenetics

1.1.5.7.1.1 Epigenetics and Cancer Treatment

1.1.5.7.2 Metabolomics

1.1.5.7.2.1 Target Identification

1.1.5.7.2.2 Target Validation

1.1.5.7.2.3 Lead Optimization

1.1.5.7.2.4 Mode of Action

1.1.5.7.2.5 Preclinical Studies

1.1.5.7.2.6 Clinical Studies

1.1.5.7.2.7 Post-Approval Studies

1.1.5.7.2.8 Diagnostics

1.1.5.7.3 Combinatorial Chemistry

1.1.5.7.3.1 Chemical Encoding

1.1.5.7.3.2 Positional Encoding

1.1.5.7.3.3 Electronic Encoding

1.1.5.7.4 Synthetic Biology

1.1.5.7.5 Systems Biology

1.1.5.7.5.1 Computer Modelling

1.1.5.7.6 Nanotechnology

2. KEY MARKET TRENDS

2.1 Drug Discovery Gets Faster, Smarter and Cheaper

2.2 Drug Discovery Being Enabled through Halogen Bonds

2.3 Drug Discovery Bolstered by New Use for Stem Cells in Targeting ALS

2.4 Personalized Medicine: Advantage Patients, Disadvantage Drug Companies

2.5 Identification of Diagnostic and Therapeutic Targets Better Enabled by Combining Plasma Screening and Genetic Screening

2.6 Source of New Drug Category from Trapping Malaria Parasites inside Host Blood Cell

2.7 Fighting Malaria Drug Resistance through an Innovative Method

2.8 Drug Screening in 3D Using High-Throughput Chip

2.9 Drug Discovery Expedited through 3D Protein Mapping

2.10 Drug Discovery and Automated Cell Staining

2.11 Drug Discovery and Development for Complex Disease Targets to be Alleviated through a Computer Program

3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE

USPTO Issues '979 Patent for Biohaven's Glutamate Modulating Agents to Treat GAD

Patents Issued for Suven's New Chemical Entities to treat Neurodegenerative Disorders

Japan Patent Office Approves Patent for C4XD's Technology

Additional Patents Issued on MorphoSys' Ylanthia in the US and in China

Sareum Receives a Patent for its Kinase Inhibitors in Japan

USPTO Grants Patent for Prima BioMed's CVac

Japan Patent Office Decides to Issue Patent for Marina's SMARTICLES® Nucleic Acid Delivery Technology

USPTO Grants a Patent in Regulus' Sarnow Patent Estate on microRNA Therapies to Treat HCV

USPTO Grants Patent for Kadimastem's Cell Technology

USPTO Grants a Novel Patent in Alnylam's McSwiggen Patent Estate

Suven Receives Patent Approval in the US for its Major Depressive Disorder Drug

Notice of Allowance for Canadian Patent Granted to VistaGen

Issue of Patent on Broad Institute's New Gene-Editing Method

US Patent Office Grants Patent for HUB's Method of Growing Organoids

Dyadic Granted US Patent for High Throughput Screening

US Patent Granted to Theranostics Health

Reveleris Flash Chromatography System Receives Patent from the Australian Patent Office

Sareum Receives Patent for one of its CHK1 Cancer Programme-related Inventions in the US

Lpath's iSONEP Receives Patent from USPTO

KeyGene Obtains Patent for High Throughput Screening in the US

BioInvent's F.I.R.S.T. Drug Discovery Technology Gets Patent in the US

Plasticell Receives Additional Patents for its CombiCult® Cell Culture Technology in the US, Europe, Australia and Singapore

EntomoPharm Receives Patent for its BBB Insect Model in Europe

Summit Gets Patent for Utrophin Modulator SMT C1100 in the US

USPTO Grants Patent to OncoMed for Methods of Treating Cancer with its Antibody Vantictumab

Novel Component of Phylomer® Peptide Platform Patented by Phylogica for Advanced Cell-Penetrating Drug Discovery

COTI Receives Two Newly Granted Patents for its Lead Oncology Asset in the US

4. KEY GLOBAL PLAYERS4-Antibody AGAbbott LaboratoriesAccelrys, Inc.Affymetrix Inc.Agilent Technologies Inc.Asahi Kasei Pharma CorporationAstrazeneca PlcAviva Biosciences Corp.Bayer Healthcare AGBD BiosciencesBeckman Coulter Inc.Biacore International ABBioanalytical Systems, Inc.Bio-Rad Laboratories, Inc.Boehringer Ingelheim GmbHBristol-Myers Squibb CompanyCaliper Life Sciences, Inc.Caprion Proteomics, Inc.Celera CorporationCelgene CorporationCharles River Laboratories International, Inc.Compugen Ltd.Decode Genetics, Inc.EMD Millipore CorporationEvotec AGGE Healthcare Ltd.Genedata AGHitgen LtdHudson Robotics, Inc.Illumina Inc.Incyte CorporationIsis Pharmaceuticals, Inc.Kyowa Hakko Kirin Co., Ltd.Luminex CorporationMaxcyte, IncMerck & Co., Inc.Millennium Pharmaceuticals, Inc.Molecular Devices, LLCMolecular Discovery Ltd.Molecular Discovery Systems Pty., Ltd.New England Biolabs, Inc.Novartis AGOsiris Therapeutics Inc.Perkinelmer, Inc.Promega CorporationQiagen N.V.Quantum PharmaceuticalsRoche Holding AGShimadzu CorporationSigma-Aldrich CorporationSri BiosciencesTecan Group Ltd.The National Center for Drug ScreeningThermo Fisher Scientific Inc.Viva Biotech LtdWaters Corp.

5. KEY BUSINESS TRENDS

Evotec Established Alliance with Eternygen on New Small Molecule Inhibitors Development

MRC Technology Partnered With Daiichi Sankyo to Discover New Drug Targets

Evotec, Debiopharm Group™ to Discover New Drugs to treat Cancer

Daiichi Sankyo Forms Alliance with UCSF on New Cures Development to Treat Neurodegenerative Diseases

Debut of a Synergetic Drug Discovery Project for 2014 by Daiichi Sankyo

Analgesic Drug Discovery and Development Collaboration Formed by Convergence and Evotec

MIT SBC, Pfizer Enter into a Three-Year Drug Discovery Research Alliance

Abide, Celgene Partners to Discover and Develop Novel Drugs to Treat Inflammation and Immunological Disorders

Novel Genetic Platform Having the Ability to Yield Natural Microbial Genomes

Johnson & Johnson Innovation Signs Novel Agreements with NEOMED and MaRS Innovation

Boehringer Ingelheim and Circuit Therapeutics Form Drug Discovery Research Pact for Three Years

Life Technologies and NCATS form RNAi Research Alliance to Enhance Novel Therapeutics Discovery

Novel Core Unit of USTAR and U of U Eases Pharmacological Therapeutic Development

JHL Biotech Inks Strategic Collaboration with Selexis to Develop Biologic Drugs

Bayer Offer Funding to the SGC for Expediting Drug Research

HitGen, the University of Manchester's Cancer Research UK Manchester Institute Drug Discovery Group and Cancer Research Technology Form Drug Discovery Pact

BioFocus, Boehringer Ingelheim Enter Into Drug Discovery Pact

Evotec Establishes Drug Discovery Alliance with Johnson & Johnson Innovation on AD Targets

Release of GE Healthcare Life Sciences' Novel Xuri™ Technology Family

4SC Discovery, CRELUX and AiCuris Form Drug Discovery Pact

Novel SLAP Technology for Drug Discovery Advancements

Inauguration of GE Healthcare Life Sciences Technology Laboratory at the UK's First Open Innovation Bioscience Campus

Debut of an "Open Innovation" Research Alliance by AstraZeneca and Taiwan's NRPB to Accelerate Drug Discovery

Asahi Kasei Pharma and Vernalis plc Collaborate to Discover Drugs for Autoimmune Diseases

Launch of Thermo Fisher Scientific's Novel Innovations at BioProcess International Conference and Exhibition

Adimab Establishes Alliance with Celgene on Multi-target Discovery

Eurofins Scientific, GE Healthcare Enter Pact on Drug Discovery Services

Debut of Boehringer Ingelheim and Polyphor into the Next Research Stage of their Alliance

Commercial Release of Agilent's RapidFire 365 High-Throughput Mass Spectrometry System

Zalicus Plans to Advance Clinical Development of Z944

Debut of Kinexus' DrugKiNET KnowledgeBase

Evotec Establishes Alliance with Harvard University to Develop Novel Antibacterial Agents

UCSF Turns to be the First Partner of Pfizer's CTI in Both Small-Molecule and Biologics Discovery

In-House Development of Various Novel Antiviral Drugs from Achillion

Launch of Thermo Fisher Scientific's Drug Discovery and Biopharma Production Innovations

Sareum Partners with SRI International for Advancing the Clinical Development of Tyrosine Kinase 2 Small Molecule Drug Discovery Program

Launch of Hudson Robotics' High Efficiency Screening, an Advanced Drug Discovery Technology

Accelrys Insight and Accelrys Insight for Excel Drug Discovery Softwares from Accelrys, Inc

Renewal of Evotec and Genentech's Drug Discovery Collaboration

Alchemia, AstraZeneca Form Multi-Target Drug Discovery Pact

RaQualia Establishes Research Alliance with Interprotein to Discover PPI Inhibitor

Collaborative Effort of Evotec and Ono Yields Novel Compounds for Preclinical Development

Galapagos Takeover Cangenix Assets

EMD Millipore's Novel Genomic Biomarker Services

Marketing of an Advanced Metabolite-Identification Platform by Agilent and Molecular Discovery

QuantiGene® ViewRNA Assay Platform-based Novel Cancer Biomarker Tests Co-developed by Affymetrix and MGH

Numerate and Merck Partnered to Discover Drug Leads for Cardiovascular Disease Target

Evotec Partners with IR Pharma to Offer Drug Discovery Solutions in the Area of Respiratory Diseases

6. GLOBAL MARKET OVERVIEW6.1. Global Market Overview by Technology6.1.1 Drug Discovery Technology Overview by Global Region6.1.1.1 Bioanalytical Assays6.1.1.2 Bioinformatics6.1.1.3 Cell Based Assays6.1.1.4 Genomic Technologies6.1.1.5 High Throughput Screening6.1.1.6 Proteomic Technologies6.1.1.7 Other Drug Discovery Technologies

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES

1.1 United States Market Overview by Technology

1.2 Major Market Players

Abbott Laboratories

Accelrys, Inc.

Affymetrix Inc.

Agenus Inc.

Agilent Technologies Inc.

Albany Molecular Research, Inc.

Arqule Inc.

Aviva Biosciences Corp.

BD Biosciences

Beckman Coulter Inc.

Bioanalytical Systems, Inc.

Bio-Rad Laboratories, Inc.

Biovision, Inc.

Bristol-Myers Squibb Company

Bruker Corporation

Caliper Life Sciences, Inc.

Capital Genomix, Inc.

Celera Corporation

Celgene Corporation

Charles River Laboratories International, Inc.

Discoverx Corporation

Discovery Genomics, Inc.

EMD Millipore Corporation

Hudson Robotics, Inc.

Illumina Inc.

Incyte Corporation

Isis Pharmaceuticals, Inc.

Life Technologies Corporation

Luminex Corporation

Maxcyte, Inc

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Molecular Devices, LLC

New England Biolabs, Inc.

Osiris Therapeutics Inc.

Perkinelmer, Inc.

Promega Corporation

Sigma-Aldrich Corporation

SRI Biosciences

Thermo Fisher Scientific Inc.

Waters Corp.

2. EUROPE2.1 European Market Overview by Technology2.2 Major Market Players4-Antibody AG (Switzerland)Astrazeneca Plc (United Kingdom)Bayer Healthcare AG (Germany)Biacore International AB (Sweden)Biofocus Dpi, Ltd (United Kingdom)Boehringer Ingelheim GmbH (Germany)Decode Genetics, Inc. (Iceland)Evotec AG (Germany)GE Healthcare Ltd. (United Kingdom)Genedata AG (Switzerland)Molecular Discovery Ltd. (Italy)Novartis AG (Switzerland)Qiagen N.V. (The Netherlands)Quantum Pharmaceuticals (Russia)Roche Holding AG (Switzerland)Tecan Group Ltd. (Switzerland)

3. ASIA-PACIFIC

3.1 Asia-Pacific Market Overview by Technology

3.2 Major Market Players

Asahi Kasei Pharma Corporation (Japan)

Hitgen Ltd (China)

Kyowa Hakko Kirin Co., Ltd. (Japan)

Molecular Discovery Systems Pty., Ltd. (Australia)

Shimadzu Corporation (Japan)

The National Center for Drug Screening (China)

Viva Biotech Ltd (China)

4. REST OF WORLD4.1 Rest of World Market Overview by Technology4.2 Major Market PlayersCaprion Proteomics, Inc. (Canada)Compugen Ltd. (Israel)Pluristem Therapeutics Inc. (Israel)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA

1.1 Canada

1.2 United States

2. EUROPE

2.1 Belgium

2.2 Denmark

2.3 France

2.4 Germany

2.5 Iceland

2.6 Ireland

2.7 Italy

2.8 Russia

2.9 Sweden

2.10 Switzerland

2.11 The Netherlands

2.12 The United Kingdom

3. ASIA-PACIFIC

3.1 Australia

3.2 China

3.3 India

3.4 Japan

3.5 Singapore

3.6 Taiwan

4. REST OF WORLD

4.1 Israel

PART D: ANNEXURE1. RESEARCH METHOLOGY2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVEChart 1: Global Drug Discovery Technologies Market Analysis (2010-2020) in USD MillionChart 2: Global Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD MillionChart 3: Glance at 2010, 2015 and 2020 Global Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other TechnologiesChart 4: Global Market for Bioanalytical Assays in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 5: Glance at 2010, 2015 and 2020 Global Market Share of Bioanalytical Assays in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 6: Global Market for Bioinformatics in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 7: Glance at 2010, 2015 and 2020 Global Market Share of Bioinformatics in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 8: Global Market for Cell Based Assays in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 9: Glance at 2010, 2015 and 2020 Global Market Share of Cell Based Assays in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 10: Global Market for Genomic Technologies in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 11: Glance at 2010, 2015 and 2020 Global Market Share of Genomic Technologies in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 12: Global Market for High Throughput Screening in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 13: Glance at 2010, 2015 and 2020 Global Market Share of High Throughput Screening in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 14: Global Market for Proteomic Technologies in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 15: Glance at 2010, 2015 and 2020 Global Market Share of Proteomic Technologies in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 16: Global Market for Other Drug Discovery Technologies in Drug Discovery (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD MillionChart 17: Glance at 2010, 2015 and 2020 Global Market Share of Other Drug Discovery Technologies in Drug Discovery (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

Chart 18: The Projection of Largest Regions in terms of Market Growth for Drug Discovery Technologies by Geography – Asia-Pacific, Europe and United States

Chart 19: Global Drug Discovery Technologies Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 20: Glance at 2010, 2015 and 2020 Global Drug Discovery Technologies Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

THE UNITED STATESChart 21: United States Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD MillionChart 22: Glance at 2010, 2015 and 2020 United States Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies

EUROPE

Chart 23: European Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD Million

Chart 24: Glance at 2010, 2015 and 2020 European Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies

ASIA-PACIFICChart 25: Asia-Pacific Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD MillionChart 26: Glance at 2010, 2015 and 2020 Asia-Pacific Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies

REST OF WORLD

Chart 27: Rest of World Drug Discovery Technologies Market Analysis (2010-2020) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies in USD Million

Chart 28: Glance at 2010, 2015 and 2020 Rest of World Drug Discovery Technologies Market Share (%) by Discovery Technology – Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Other Technologies

Table 1: Prominent Technologies used for Bioanalytical ResearchTable 2: Prominent Types of Cell Based Assays used in High Throughput Screening

To order this report:  Drug Discovery Technologies - A Global Market Overview

http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html 

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Technology vendors and analysts are eager to paint a rosy picture of how wonderful IoT is and why your deployment will be great with the use of their products and services. While it is easy to showcase successful IoT solutions, identifying IoT systems that missed the mark or failed can often provide more in the way of key lessons learned. In his session at @ThingsExpo, Peter Vanderminden, Principal Industry Analyst for IoT & Digital Supply Chain to Flatiron Strategies, will focus on how IoT depl...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at Dell EMC, introduced a methodology for capturing, enriching and sharing data (and analytics) across the organization...
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs, and improve customer experience – effectively the same challenges they have always had in growing their business. The exciting thing about the IoT industry is now these decisions can be better, faster, and smarter. Now ...
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
"Splunk basically takes machine data and we make it usable, valuable and accessible for everyone. The way that plays in DevOps is - we need to make data-driven decisions to delivering applications," explained Andi Mann, Chief Technology Advocate at Splunk and @DevOpsSummit Conference Chair, in this SYS-CON.tv interview at @DevOpsSummit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
"Logz.io is a log analytics platform. We offer the ELK stack, which is the most common log analytics platform in the world. We offer it as a cloud service," explained Tomer Levy, co-founder and CEO of Logz.io, in this SYS-CON.tv interview at DevOps Summit, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captur...
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...